

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**CONVENIENCE TRANSLATION INTO ENGLISH OF
CONSOLIDATED FINANCIAL STATEMENTS AT 30 SEPTEMBER 2025**

(ORIGINALLY ISSUED IN TURKISH)

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 September 2025

(Amounts expressed in thousands of Turkish Lira (‘TRY’) based on the purchasing power of the Turkish Lira (‘TL’) as of 30 September 2025, unless otherwise indicated.)

	30 September 2025 USD (*)	30 September 2025 TL	31 December 2024 TL
Current assets	425.447	17.655.394	15.809.936
Cash and cash equivalents	85.869	3.563.415	3.966.580
Trade receivables			
- Due from third parties	91.053	3.778.571	1.929.680
- Due from related parties	52.754	2.189.173	2.925.846
Other receivables			
- Due from third parties	582	24.166	1.062
Derivative financial assets	-	-	142.361
Inventories	149.285	6.195.090	5.646.481
Prepaid expenses	10.692	443.702	126.108
Current tax assets	1.057	43.884	154.115
Other current assets	34.155	1.417.393	917.703
Non-current assets	1.109.759	46.053.207	28.884.200
Financial investments	950	39.427	22.728
Investments accounted for using equity method	-	-	2.647.372
Investment properties	17.149	711.651	723.455
Property, plant and equipment	911.394	37.821.385	23.745.193
Right of use assets	6.043	250.771	166.924
Intangible assets and goodwill			
- Goodwill	29.652	1.230.493	144.731
- Other intangible assets	133.238	5.529.161	1.099.814
Prepaid expenses	11.333	470.319	333.983
Total assets	1.535.206	63.708.601	44.694.136

(*) US Dollar (‘USD’) amounts presented above have been translated from Turkish Lira (‘TL’) for convenience purposes only, at the official TL bid rate announced by the Central Bank of the Republic of Turkey (‘CBRT’) at 30 September 2025 and therefore do not form part of these consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL
STATEMENTS ORIGINALLY ISSUED IN TURKISH**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 September 2025

(Amounts expressed in thousands of Turkish Lira ('TRY') based on the purchasing power of the Turkish Lira ("TL") as of 30 September 2025, unless otherwise indicated.)

	30 September 2025 USD (*)	30 September 2025 TL	31 December 2024 TL
Current liabilities	501.596	20.815.484	12.451.123
Current borrowings			
- Current borrowings from related parties	41.536	1.723.687	3.244.969
- Current borrowing to other parties	319.080	13.241.320	3.026.189
Current portion of non-current borrowings			
- Bank loans	13.968	579.649	650.954
- Lease liabilities	573	23.763	33.638
Trade payables			
- Due to third parties	84.579	3.509.901	4.205.780
- Due to related parties	23.871	990.590	396.127
Payables related to employee benefits	1.938	80.413	52.260
Derivative financial liabilities	1.080	44.830	-
Other payables			
- Other payables to third parties	2.169	90.089	1.473
Deferred income other than contract liabilities	7.526	312.324	688.274
Current income tax liabilities	510	21.148	-
Current provisions			
- Current provisions for employee benefits	4.763	197.650	151.308
- Other current provisions	3	120	151
Non-current liabilities	285.520	11.848.588	2.294.334
Long-term borrowings			
- Bank loans	210.556	8.737.717	1.083.384
- Lease liabilities	3.171	131.533	36.835
Non-current provisions			
- Non-current provisions for employee benefits	6.526	270.839	192.044
Other non-current liabilities	21.128	876.794	4.724
Deferred tax liabilities	44.139	1.831.705	977.347
Total liabilities	787.116	32.664.072	14.745.457
EQUITY	748.090	31.044.529	29.948.679
Attributable to equity holders of the parent	725.641	30.112.941	29.948.679
Paid-in capital	93.618	3.885.000	3.885.000
Inflation adjustments on capital	174.156	7.227.214	7.227.214
Effects of business combinations under common control	1.488	61.766	-
Other accumulated comprehensive income/(loss) that will not be reclassified in profit and loss			
- Gains/(losses) on remeasurements of defined benefit plans	(2.944)	(122.191)	(142.212)
- Share of other comprehensive income of investments accounted for using equity method that will not be reclassified to profit or loss	-	-	56.180
- Other revaluation and measurement gains/losses	60	2.474	2.137
Other comprehensive income/(loss) that will be reclassified in profit and loss			
- Currency translation differences	693	28.770	1.748.710
- Gains/(losses) on hedge	-	-	(1.255.814)
Restricted reserves	103.482	4.294.338	3.985.308
Retained earnings	292.879	12.154.011	13.016.492
Net profit for the period	62.209	2.581.559	1.425.664
Non-controlling interests	22.449	931.588	-
Total liabilities and equity	1.535.206	63.708.601	44.694.136

(*) USD amounts presented above have been translated from Turkish Lira ("TL") for convenience purposes only, at the official TL bid rate announced by the CBRT at 30 September 2025 and therefore do not form part of these consolidated financial statements.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 September 2025

(Amounts expressed in thousands of Turkish Lira ("TRY") based on the purchasing power of the Turkish Lira ("TL") as of 30 September 2025, unless otherwise indicated.)

Profit or loss	2025 USD (*)	2025 TL	2024 TL
Revenue	608.396	23.436.242	27.813.147
Cost of sales (-)	(531.823)	(20.486.561)	(23.477.158)
Gross profit	76.573	2.949.681	4.335.989
General administrative expenses (-)	(24.588)	(947.145)	(624.654)
Marketing expenses (-)	(23.822)	(917.654)	(699.032)
Research and development expenses (-)	(3.481)	(134.085)	(89.260)
Other income from operating activities	81.065	3.122.729	1.434.090
Other expense from operating activities (-)	(26.787)	(1.031.871)	(1.524.363)
Profit from operating activities	78.960	3.041.655	2.832.770
Investment activity Income	47.082	1.813.663	35.586
Share of profit/(loss) of investment accounted for using equity method	(1.052)	(40.510)	(41.992)
Profit before financing income	124.990	4.814.808	2.826.364
Finance income	39.960	1.539.296	1.131.460
Finance expense (-)	(125.500)	(4.834.425)	(1.947.082)
Monetary gain/(loss), net	18.973	730.859	443.396
Profit/(loss) from continuing operations, before tax	58.423	2.250.538	2.454.138
Tax (expense)/income, continuing operations			
- Current period tax expense (-)	(2.761)	(106.344)	(572.566)
- Deferred tax expense	10.455	402.729	(416.510)
Profit from continuing operations	66.117	2.546.923	1.465.062
Attributable to:			
Owners of parent	67.016	2.581.559	1.465.062
Non-controlling interests	(899)	(34.636)	-
Basic earnings per share from continuing operations (Kr)	0.66	0,66	0,38
Other comprehensive income/(loss):			
Other comprehensive income that will not be reclassified to profit or loss			
Gains /(losses) on remeasurements of defined benefit plans	684	26.343	43.970
Gains/(losses) on remeasurements of defined benefit plans of associates and joint ventures accounted for using equity method	(78)	(3.023)	(13.767)
Taxes relating to components of other comprehensive income that will not be reclassified to profit or loss	(164)	(6.322)	(10.553)
Other revaluation increases	9	337	(43)
Other comprehensive income that will be reclassified to profit or loss			
Other comprehensive income / (loss) related with cash flow hedges	42.895	1.652.387	439.693
Currency translation differences	1.500	57.794	(133.135)
Taxes relating to components of other comprehensive income that will be reclassified to profit or loss	(10.295)	(396.573)	(105.526)
Total comprehensive income	100.668	3.877.866	1.685.701
Attributable to:			
Owners of parent	101.567	3.912.502	1.685.701
Non-controlling interests	(899)	(34.636)	-
	100.668	3.877.866	1.685.701

(*) USD amounts presented above have been translated from Turkish Lira ("TL") for convenience purposes only, at the USD average CBRT bid rates for the period ended 30 September 2025 and therefore do not form part of these consolidated financial statements.